We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Israeli medical devices company Sight Diagnostics has received $71m in Series D financing round, participated by Koch Disruptive Technologies, Longliv Ventures and OurCrowd. The funding round is aimed
Fujirebio Diagnostics, a subsidiary of Fujirebio Holdings, has begun clinical testing of its new Lumipulse SARS-CoV-2 Antigen assay, used on the LUMIPULSE G1200 device. The company said that
As businesses grapple with reopening procedures, national telehealth provider MeMD has launched the COVID-19 Workplace Solution, a standalone, turnkey solution that helps employers combat the pandemic head on.
CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) a leading developer of regenerative biomaterial compositions and medical devices, today announced European Patent Office patent claim allowances for European Community (EC) Patent Application
Abiomed has received the US Food and Drug Administration (FDA) emergency use authorisation (EUA) for its left-sided Impella heart pumps to support therapy for Covid-19 patients. Covid-19 causes
Abbott has initiated enrolling first patients in the TactiFlex PAF IDE study to evaluate a new device to treat paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat.
Eurofins Technologies (Paris:ERF) announces the launch of reagents for automated isolation of high-quality SARS-CoV-2 RNA (ribonucleic acid) from viral particles of human respiratory specimens. The reagents’ magnetic bead-based,
Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the worldwide leader in MRI-guided cardiac ablation products, is pleased to announce the first sales collaboration with Philips, a global
Eko today announced a global collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure. Through the
Texas-based molecular diagnostics company Asuragen has entered into a clinical research collaboration with Pacific Biosciences of California (PacBio), a biotechnology company. The collaboration is aimed at developing molecular